Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN

Capricorn Fund Managers Ltd acquired a new stake in Evommune, Inc. (NYSE:EVMN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 60,000 shares of the company’s stock, valued at approximately $1,027,000. Capricorn Fund Managers Ltd owned about 0.19% of Evommune as of its most recent SEC filing.

Evommune Price Performance

EVMN opened at $23.58 on Monday. The firm has a fifty day moving average price of $24.06. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $33.20. The company has a market cap of $849.32 million and a P/E ratio of -2.92.

Evommune (NYSE:EVMN) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Analysts Set New Price Targets

Several equities research analysts have issued reports on EVMN shares. Wall Street Zen raised Evommune from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Oppenheimer initiated coverage on shares of Evommune in a report on Thursday, January 22nd. They issued an “outperform” rating and a $42.00 price objective on the stock. Raymond James Financial started coverage on shares of Evommune in a research note on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 target price for the company. Weiss Ratings initiated coverage on shares of Evommune in a report on Tuesday, February 3rd. They set a “sell (e)” rating for the company. Finally, The Goldman Sachs Group upgraded shares of Evommune to a “buy” rating in a research note on Wednesday, January 7th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $47.17.

Evommune Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.